What NAD+ Does in the Body

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell. In its most basic role it shuttles electrons during the chemical reactions that convert food into usable energy (ATP) inside mitochondria. Beyond energy production, NAD+ serves as a required substrate for several enzyme families: sirtuins that help regulate gene expression and stress responses, PARP enzymes involved in DNA repair, and CD38, which participates in calcium signaling and immune function. When NAD+ availability drops, these systems operate less efficiently.

NAD+ Levels and Aging

Multiple human tissue studies show lower NAD+ concentrations in skeletal muscle and other organs with advancing age. The decline is linked to reduced activity of the biosynthetic enzyme NAMPT and increased activity of NAD+-consuming enzymes such as CD38, which rises with chronic low-grade inflammation. While recent measurements of whole-blood NAD+ have not always shown a clear age-related drop, tissue-level reductions remain consistent with preclinical models and with functional associations—lower muscle NAD+ correlates with reduced mitochondrial capacity and physical performance in older adults.

Oral Precursors: NR and NMN

Two widely studied oral precursors are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both raise circulating NAD+ levels in human trials, often roughly doubling blood concentrations after one to two weeks of daily dosing in the 250–1000 mg range. Some studies report modest improvements in walking speed, grip strength, or sleep quality in older participants, although functional outcomes remain mixed across trials. Oral forms are convenient and generally well tolerated, yet they rely on absorption and conversion pathways that can limit the speed and peak tissue exposure compared with direct injection delivery.

Injectable NAD+: Immediate Sensation and Longer Effects

Direct injection or intravenous infusion of NAD+ bypasses the digestive tract. Many people report a noticeable physical sensation within seconds to minutes—warmth, flushing, mild chest pressure, or abdominal cramping. These effects are common, especially in individuals receiving NAD+ for the first time, and typically resolve within one to two minutes once the infusion rate is slowed or the injection is complete. Because the sensation can be intense, clinical protocols usually begin with low doses (commonly 25–50 mg for intramuscular or subcutaneous routes, or a slow drip of a higher total dose for IV) and increase only if tolerated.

Pharmacokinetic data show that infused NAD+ is rapidly cleared from plasma, yet cellular uptake and subsequent effects on energy metabolism and repair pathways can persist. Users frequently describe improvements in energy, mental clarity, and recovery that last for several days after a single session. Formal large-scale outcome trials of injectable NAD+ for general health optimization remain limited; most available human evidence consists of small pharmacokinetic studies, retrospective clinic series, and individual reports. Still, the combination of rapid sensory feedback and multi-day subjective duration distinguishes injectable NAD+ from oral precursors for many people seeking a more immediate and pronounced response.

Practical Considerations

Starting low and titrating upward under medical supervision reduces the intensity of acute sensations while allowing the individual to find a tolerable and effective dose. Hydration, slow administration, and occasional premedication strategies are commonly used to improve comfort. Injectable NAD+ is not a substitute for foundational habits—sleep, resistance training, protein intake, and management of inflammation—but it can be one component of a broader plan aimed at supporting cellular energy systems.

Coordinating NAD+ With Hormone and Peptide Strategies

Because cellular energy status interacts with hormone signaling and recovery capacity, many adults evaluate NAD+ alongside other interventions. Clinicians who review full hormone panels and recovery markers can help determine whether NAD+ fits within an existing program. Services available through Vita Bella provide access to supervised hormone and peptide protocols that can be coordinated with NAD+ use when clinically appropriate.

For individuals already working with peptide or hormone therapies and seeking additional cellular-support options, the same clinical teams at Vita Bella can integrate laboratory monitoring and individualized dosing guidance.

References

1. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. doi:10.1038/s41580-020-00313-x

2. Janssens GE, et al. Healthy aging and muscle function are positively associated with NAD+ abundance in humans. Nat Aging. 2022;2(3):254-263. doi:10.1038/s43587-022-00174-3

3. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. doi:10.1126/science.abe9985

4. Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43. doi:10.1007/s11357-022-00705-1

5. Grant R, Berg J, Mestayer R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci. 2019;11:257. doi:10.3389/fnagi.2019.00257

6. Trętowicz MM, et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nat Metab. 2026;8:1282-1290. doi:10.1038/s42255-026-01537-5

7. Clinical observations and retrospective series on intravenous and intramuscular NAD+ administration, including tolerability data from real-world infusion settings (2024–2026 reports).